Pharma Mar SAU
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a syntheti… Read more
Pharma Mar SAU (PHMMF) - Total Liabilities
Latest total liabilities as of September 2025: $140.06 Million USD
Based on the latest financial reports, Pharma Mar SAU (PHMMF) has total liabilities worth $140.06 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pharma Mar SAU - Total Liabilities Trend (2002–2024)
This chart illustrates how Pharma Mar SAU's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pharma Mar SAU Competitors by Total Liabilities
The table below lists competitors of Pharma Mar SAU ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Port of Tauranga Limited
OTCGREY:PTAUF
|
USA | $717.00 Million |
|
Huada Automotive Tech Corp Ltd
SHG:603358
|
China | CN¥3.29 Billion |
|
Ferrotec Corporation
F:FER
|
Germany | €286.00 Billion |
|
Winmark Corporation
NASDAQ:WINA
|
USA | $80.09 Million |
|
Guangdong Baolihua New Energy Stock Co LTD
SHE:000690
|
China | CN¥9.39 Billion |
|
China Southern Power Grid Technology Co Ltd
SHG:688248
|
China | CN¥1.56 Billion |
|
Hydsoft Technology Co. Ltd. A
SHE:301316
|
China | CN¥789.54 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down Pharma Mar SAU's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharma Mar SAU's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharma Mar SAU (2002–2024)
The table below shows the annual total liabilities of Pharma Mar SAU from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $141.28 Million | -3.94% |
| 2023-12-31 | $147.08 Million | -13.63% |
| 2022-12-31 | $170.30 Million | -10.59% |
| 2021-12-31 | $190.47 Million | -16.29% |
| 2020-12-31 | $227.54 Million | +94.06% |
| 2019-12-31 | $117.25 Million | -16.37% |
| 2018-12-31 | $140.20 Million | -14.89% |
| 2017-12-31 | $164.74 Million | -4.58% |
| 2016-12-31 | $172.64 Million | +24.29% |
| 2015-12-31 | $138.90 Million | -1.71% |
| 2014-12-31 | $141.32 Million | +0.99% |
| 2013-12-31 | $139.94 Million | -13.14% |
| 2012-12-31 | $161.10 Million | -12.12% |
| 2011-12-31 | $183.31 Million | -6.45% |
| 2010-12-31 | $195.96 Million | +15.15% |
| 2009-12-31 | $170.18 Million | +7.57% |
| 2008-12-31 | $158.20 Million | +18.49% |
| 2007-12-31 | $133.51 Million | +13.89% |
| 2006-12-31 | $117.23 Million | +248.07% |
| 2005-12-31 | $33.68 Million | -6.72% |
| 2004-12-31 | $36.11 Million | -73.49% |
| 2003-12-31 | $136.20 Million | +30.29% |
| 2002-12-31 | $104.53 Million | -- |